Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer

An immunotherapy, cancer cell technology, applied in chemical instruments and methods, metabolic diseases, immunoglobulins, etc., can solve problems such as exhaustion, interference, long-term immunosuppression, etc.

Active Publication Date: 2013-10-09
汤姆 C 臧
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Repeated or high-dose cycles of chemotherapy may cause severe stem cell depletion leading to long-term immunosuppression or failure
Immunosuppression and other side effects often limit the dose or frequency of treatment, interfere with other treatments used in combination with chemotherapy, or otherwise cause interruptions in cancer treatment and progression of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
  • Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
  • Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] Example 1: Metabolic Targeted Chemotherapy Has Beneficial Clinical Effects

[0131] patient. Six patients with several metabolically advanced cancers (i.e. stage IIIB / IV) that had not previously responded to standard treatment with one or more chemotherapeutic agents, radiation, surgery, or other forms of treatment were selected and performed as follows treat.

[0132] treatment solutions. Before treatment, patients were imaged by computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), or a combination thereof, and baseline tumor mass was calculated. On Day 0, patients are fasted overnight to achieve baseline glucose levels (typically about 4.5-5.5 mmol / L). The next day (Day 1), after an initial IV infusion with 500 cc of saline, all patients received insulin (Humalog) intravenously (i.v.) at a dose of 0.1 to 0.5 units / kg body weight to lower blood glucose levels to baseline About half of the level (about 2.2-2.8mmol / L). ...

Embodiment 2

[0144] Example 2: Metabolic Targeted Chemoimmunotherapy for the Treatment of Cancer

[0145] patient. Select patients with several metabolically advanced cancers (i.e., stage IIIB / IV; cancer types are shown in Table 4 below) that have not previously responded to standard treatment with one or more chemotherapeutic agents, radiation, surgery, or other forms of treatment Patients who were treated at No. 383 Changying East Road, Xi'an Xincheng Borui Hospital and Yangling Demonstration Area Hospital were treated as described below.

[0146] treatment solutions. Before treatment, patients were imaged by computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), or a combination thereof, and baseline tumor mass was calculated.

[0147] On day 0, the patient is administered an immunizing agent such as a therapeutic antibody or functional fragment thereof. Therapeutic antibodies that may be used in this treatment regimen may include commerci...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for treating cancer comprising administering a metabolic targeting chemo-immunotherapy regimen are provided herein. In one embodiment, the metabolic targeting chemo-immunotherapy regimen may include steps of administering a therapeutically effective dose of one or more immunologic agents (e.g., a therapeutic antibody) to stimulate an immune response in a subject having cancer; reducing the patient's blood glucose level; and administering a therapeutically effective dose of one or more chemotherapeutic agents. The methods desecribed herein may be used to treat any type of cancer, especially malignant and metastatic late stage cancers.

Description

[0001] priority statement [0002] This application claims the benefit of US Provisional Application No. 61 / 420,208, filed December 6, 2010, which is hereby incorporated by reference in its entirety as if set forth in its entirety herein. Background technique [0003] Cancer is the leading cause of death worldwide. In the United States alone, more than 1.3 million people are diagnosed with cancer and more than 500,000 die each year. Due to high morbidity and mortality, research efforts have focused on improving treatment options for those already diagnosed with cancer, but a cure has been elusive, especially in the advanced stages of the disease. [0004] Treatment options are determined based on the type and stage of cancer and the patient's overall health. Several treatment options are available, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Sometimes early-stage primary tumors are treated with surgery followed by radiation thera...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/475A61K31/282A61K31/513A61K31/704A61K31/7048A61K38/28A61K39/395A61K45/00A61P35/00A61P35/04A61K33/243
CPCA61K31/675A61K31/475A61K31/519A61K31/704A61K39/39558A61K31/36A61K31/555A61K31/407A61K45/06A61K31/64A61K31/513A61K31/49A61K31/7068A61K31/7048A61K33/24A61K31/277A61K31/155A61K38/28C07K16/2863C07K16/32A61K38/191A61K38/193A61K38/2026A61K38/217A61K2039/545A61K31/4745A61K31/573A61P35/00A61P35/02A61P35/04A61P37/04A61P43/00A61P3/10A61K33/243A61K2300/00
Inventor 汤姆·C·曾琳达·米德-托林迈克尔·E·彭宁顿
Owner 汤姆 C 臧
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com